Fig. 3From: Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasisRadiation necrosis-free survival (RNFS) rates for all patients after 1 and 2 years were 87.9 and 81.7%, respectively (a). The estimated 1-year RNFS rates were 90.0 and 82.1% for stereotactic radiosurgery (SRS) with concurrent targeted/ immunotherapy (TT/IT) and SRS alone (p = 0.935) (b)Back to article page